ACARIX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2635 SEK | +0.38% |
|
+13.33% | +38.83% |
| 04-29 | Acarix Receives Order from the First Freestanding Emergency Room in the Us | CI |
| 04-11 | Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study | CI |
| Sales 2024 * | 86.9M 8.04M 640M | Sales 2025 * | 191M 17.69M 1.41B | Capitalization | 209M 19.3M 1.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -24M -2.22M -177M | Net income 2025 * | 58M 5.36M 427M | EV / Sales 2024 * | 2.36 x |
| Net cash position 2024 * | 4M 370K 29.48M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.09 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
2.64
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Acarix AB
More press releases
| 1 day | +0.38% | ||
| 1 week | +13.33% | ||
| Current month | +4.98% | ||
| 1 month | +6.68% | ||
| 3 months | +19.77% | ||
| 6 months | +14.57% | ||
| Current year | +38.83% |
1 week
0.23
0.27
1 month
0.210.30
Current year
0.180.37
1 year
0.180.64
3 years
0.181.96
5 years
0.186.30
10 years
0.1826.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 60 | 31/12/06 | |
| Director of Finance/CFO | 60 | 31/12/15 | |
Jennifer Matson
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 51 | 10/05/21 | |
Ulf Rosén
BRD | Director/Board Member | 64 | 31/12/13 |
| Director/Board Member | 70 | 10/05/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 0.2635 | +0.38% | 1,172,096 |
| 02/05/24 | 0.2625 | +4.58% | 2,265,302 |
| 30/04/24 | 0.251 | +0.40% | 1,347,162 |
| 29/04/24 | 0.25 | +8.70% | 3,843,815 |
| 26/04/24 | 0.23 | -1.08% | 5,188,192 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 04:16 pm
More quotes
Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Companyâs primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.
Calendar
13/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.83% | 19.07M | |
| -14.68% | 18.57B | |
| -42.33% | 2.82B | |
| +17.00% | 1.85B | |
| -0.51% | 1.66B | |
| +27.15% | 1.23B | |
| -13.90% | 989M | |
| -21.76% | 896M | |
| -2.72% | 734M | |
| -23.95% | 667M |
- Stock Market
- Equities
- ACARIX Stock
